MRSH · Marsh & Mclennan Companies, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Insurance Brokers — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MRSH
this stock
Marsh & Mclennan Companies, Inc.
|
$84.42B | -4.6% | +10.3% | 21.6 | 1.4% |
|
AON
Aon plc
|
$64.21B | -14.2% | +7.7% | 16.7 | 1.8% |
|
AJG
Arthur J. Gallagher & Co.
|
$61.59B | -7.1% | +10.1% | 39.9 | 2.6% |
|
WTW
Willis Towers Watson PLC
|
$29.31B | -4.0% | -2.2% | 19.6 | 2.6% |
|
BRO
Brown & Brown, Inc.
|
$22.15B | -17.0% | +22.8% | 18.6 | 4.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MRSH | -6.1% | -6.2% | +0.2% | -6.8% | -4.6% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -5.0% | -4.5% | -17.6% | -6.4% | -16.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.